83.9 F
San Fernando
Tuesday, Aug 9, 2022
-Advertisement-

Amgen Completes Abgenix Purchase

Thousand Oaks-based Amgen announced it has completed a $2.2 billion acquisition of Abgenix Inc., which works in the field of human therapeutic antibodies. The final regulatory approvals were received in January, and Abgenix stockholders approved the acquisition at a March 29 meeting. “Our supportive care products have helped more than six million patients with many different cancers fight their disease. The completion of this acquisition underscores our commitment to therapeutic oncology and our confidence in both panitumumab and denosumab,” said Kevin Sharer, CEO of Amgen. “We welcome the Abgenix staff into our organization and are confident that our combined manufacturing expertise and expanded capacity will help ensure that we can deliver panitumumab to every patient, every time, following FDA approval. I’d like to thank the Abgenix staff and executive team for their hard work, dedication and continued commitment during this important transition.”

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-